Reliq Health Techniques (RHT.V)

He recommended it two years ago. Recently they warned that revenues would be delayed. They have governance issues too. He sold his shares. He saw too many red flags and expects lawsuits against them. He feels bad, because he recommended this stock. He has no confidence in management. Sometimes you have to take your lumps.

Unfortunately their technology has been slowing getting out into the market and now they have a receivables collection financial issue. It does not look good, he says.

(A Top Pick Oct 12/17, Up 175%) It is advanced monitoring in the home. There are delays in their hardware. The market is starting to question if they will miss their guidance for the end of the year.

A high-risk company in an interesting space. Healthcare providers and governments want to keep people out of hospitals, so Reliq benefits. Reliq's technology can monitor people recovering from home. They're signing contracts in Texas. They target $26 million annual recurring revenue. They've had a few product missteps, so they need to deliver that $26 million target. They're also in the process of signing contracts in Canada and Australia. This could be a big business one day, but there's a lot of risk here.

This is a tele-health business that provides technology to provide alerts on patient status. It is a good risk-reward at these levels. They just announced another pilot project with doctors in Australia. He sees great growth opportunity in the future.

They started to do Beta testing on this new software, then starting onboarding clients. The stock had ran up, then recently pulled back. Then, they ran into delays onboarding clients due to a hardware issue They should be back on track now. This will generate huge cash flow as they add subscribers; it will continue to grow as in-home patient services grows.

He still owns this. They had some hardware issues for products that offer diabetes monitoring. Their recent earnings have been hinting at weaker operations as they could only recognize 2 months of revenue. It is underfollowed and he thinks there is still great growth opportunity with a long runway. He intends to continue to hold it.

The internet of things meets home healthcare. It should keep people healthier and out of the hospital. It is looking a little expensive, but if they get more contracts and prove the demand is there then it will do really well. Give them 2 years.

They do recommend it in one of their portfolios. The health monitoring business is growing and he would like to see more contracts signed. There are risks as this has a high valuation. He likes the management team. It is a speculative buy.

It is in a good area. Health care in Canada on a monthly basis is number 2 out of the sectors he ranks in Canada. This company is not for the faint of heart. It based for a long time and then exploded higher.

A past pick and still likes it. The CEO has done an excellent job of delivering on her promises. They monitor healthcare in people's homes. They've announced partnerships with several health authorities, The CEO aims for 30,000 patients
online at USD$50/month. This could lead to impressive cash flow, then later get taken out. Offers an impressive rate of growth.